Abstracts come and go, but new trials and new mechanisms stay with us for the long haul. One of the more interesting new mechanisms is the FcRn drugs, and at ACR Convergence 2026 we got to see positive results from the Phase 3 ALKIVIA trial for efgartigimod.
All News
When a patient fails a drug, we tend to consider what will be the next drug. Most of our clinics have patients on their second or third advanced therapy. Drug failure has become more common, not less. A question that we too rarely write in the notes is why did the last drug fail?
Several abstracts presented at ACR 2026 provide new insights into the potential benefits of early biologic treatment in SLE.
Today the ACR began with the Great Debate, an intriguing set of Plenary presentations, a never-ending poster hall and a plethora of stimulation oral presentation sessions. Here are a few of my favorites from today:
The first multicenter series of pregnancies after CAR T-cell therapy for autoimmune disease reports 8 healthy births and no maternal flares. It is the first dataset of its kind, and the numbers are small.
Zeng et al. TARA phase 3 RCT from China. 459 bDMARD-IR patients. Girocitinib (JAK1/TYK2i) superior to tofacitinib in RA. Better by week 4 and increasingly so over time. Numerically less serious adverse events 3.9% vs 6.6% also. @RheumNow #ACR26 Abstr#LB21 #ACRbest https://t.co/Yt406T3eyi
Park et al. Phase 2 RCT from Korea. Stem cell and cartilage acellular matrix combination injection for knee OA. Single injection provides 6-month benefits in pain, function, MRI findings, biomarkers vs placebo. @RheumNow #ACR26 Abstr#LB19 #ACRbest https://t.co/iw378MV2OM
